New drug test for children with EGFR-positive solid tumors
Treatments studied
Part of Cancer, Ear, nose & throat, Genetic & congenital, Kidney & urinary, Mouth & dental, Women’s health & pregnancy clinical trials.
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is between 2 and 18 years old
- Cancer is pathologically confirmed (diagnosed by tissue sample) and is EGFR-positive (has the EGFR protein)
- Cancer is relapsed, refractory, or metastatic (came back, didn't respond to treatment, or spread)
- At least one measurable tumor visible on CT or MRI scan (longest part ≥10 mm)
- Blood counts and liver/kidney function are adequate for treatment
- No severe active infections (HIV, hepatitis B or C) or uncontrolled heart/lung disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial tests a new combination of two drugs—becotatug vedotin (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—given before surgery to treat advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve surgical outcomes for patients with specific cancer markers.
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
This trial tests two new cancer-fighting drugs (becotatug vedotin and pucotenlimab) given together before surgery to treat head and neck cancer that has come back and stopped responding to previous immunotherapy. The goal is to shrink the tumor enough to make surgery safer and more effective.
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.